Oncolytics Biotech Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $84.4M
- Price
- $0.6617
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.19%
- Volume
- 821.1K
About
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Quick stats
Shares outstanding127.5M
Computed float115.1M
Float / shares90.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001129928
AI Summary
AI-generated1/16
minorbullishclinical trial
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics Biotech announced positive preclinical results pairing pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, with pelareorep activity maintained in the presence of RAS inhibition and no evidence of antagonism between the two therapies.
During initial every-other-day dosing the combination produced the greatest tumor reductions, though pelareorep's incremental activity became less evident once dosing shifted to weekly — a finding the company says supports further work on optimized dosing schedules.
Chief Medical Officer Thomas Heineman called the data an encouraging first look at combining pelareorep with one of the most important emerging classes of targeted cancer therapies, framing RAS-inhibitor resistance as the opportunity pelareorep could address.
Oncolytics plans to expand preclinical evaluation across additional dosing schedules and RAS-driven tumor models; the data are preclinical only and, per the company's own forward-looking statement language, may not be predictive of clinical results.
Red flags
- Preclinical data only — company's own disclaimer states results may not be predictive of clinical studies
- Pelareorep's incremental activity became less evident at less frequent weekly dosing
- Company is still 'actively pursuing strategic partnerships' with none announced